Skip to main content
. 2020 Nov 26;8(22):5576–5588. doi: 10.12998/wjcc.v8.i22.5576

Table 3.

Differences of glycemic control efficacy in dipeptidyl peptidase-4 inhibitors group vs non-dipeptidyl peptidase-4 inhibitors group (n = 444)

Parameter
DPP4i (n = 111)
Non-DPP4i (n = 333)
P value4
Glycemic control efficacy during hospitalization
Median of FBG, median (IQR) 8.01 (6.75-10.31) 8.35 (6.48-11.12) 0.84
Median of GLU, median (IQR) 10.55 (8.70-12.58) 10.70 (8.90-13.45) 0.90
Max FBG, median (IQR) 11.18 (7.82-13.92) 10.50 (7.33-15.48) 0.95
Max GLU, median (IQR) 14.90 (12.40-19.10) 16.30 (13.30-20.55) 0.30
Min FBG, median (IQR) 6.67 (5.30-7.98) 6.74 (5.39-8.76) 0.54
Min GLU, median (IQR) 7.10 (5.00-9.30) 7.10 (5.65-8.90) 0.87
FBG > 7 mmol/L, day/total days1 (%) 9.09 (4.26-16.67) 6.52 (2.67-13.64) 0.05
GLU > 11.1 mmol/L, day/total days2 (%) 9.09 (5.56-23.75) 10.00 (4.08-25.40) 0.81
Titrating time3, median (IQR) 4.00 (1.00-9.00) 3.00 (1.00-11.00) 0.71
1

The day/total days of FBG > 7 mmol/L was defined as the days with FBG > 7 mmol/L as a percentage of the entire observation period.

2

The day/total days of GLU > 11.1 mmol/L was defined as the days with GLU > 11.1 mmol/L as a percentage of the entire observation period.

3

Titrating time was defined as the number of days that FBG met the normal range for the first time since admission.

4

P values were calculated based on Kruskal-Wallis rank sum test.

Data are n (%) or medians (IQR). DPP4i: Dipeptidyl peptidase-4 inhibitors; FBG: Fasting blood glucose; GLU: Random blood glucose; Max: Maximum; Min: Minimum; IQR: Interquartile range.